WallStreetZenWallStreetZen

NYSE: RDY
Dr Reddys Laboratories Ltd Earnings & Revenue

RDY past earnings growth

How has RDY's earnings growth performed historically?
Company
31.71%
Industry
3.87%
Market
36.92%
RDY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RDY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RDY's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RDY past revenue growth

How has RDY's revenue growth performed historically?
Company
8.85%
Industry
226.28%
Market
161.09%
RDY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
RDY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
RDY's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

RDY earnings and revenue history

Current Revenue
$2.8B
Current Earnings
$309.3M
Current Profit Margin
11%
RDY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

RDY Return on Equity

Current Company
13%
Current Industry
16.3%
Current Market
38.4%
RDY's Return on Equity (13%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when RDY announces earnings.

RDY Return on Assets

Current Company
8.4%
Current Industry
5%
RDY is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

RDY Return on Capital Employed

Current Company
16.73%
Current Industry
9.8%
RDY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RDY vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
RDY$2.73B$575.00M$300.61M+5.35%+10.90%
ELAN$4.54B$812.00M-$120.00M+10.73%N/A
TEVA$15.14B$191.00M-$1.29B-5.72%N/A
CTLT$4.83B$1.03B$421.00M+17.25%+21.71%
PRGO$4.40B$324.50M-$107.30M-2.50%N/A

Dr Reddys Laboratories Earnings & Revenue FAQ

What was RDY's earnings growth in the past year?

As of Q1 2023, Dr Reddys Laboratories's earnings has grown 31.71% year over year. This is 27.84 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 3.87%. Dr Reddys Laboratories's earnings in the past year totalled $300.61 million.

If you're new to stock investing, here's how to buy Dr Reddys Laboratories stock.

What was RDY's revenue growth in the past year?

As of Q1 2023, Dr Reddys Laboratories's revenue has grown 8.85% year over year. This is 217.43 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 226.28%. Dr Reddys Laboratories's revenue in the past year totalled $2.73 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.